Eleanor J Cole 1, Angela L Phillips 1, Brandon S Bentzley 1, Katy H Stimpson 1, Romina Nejad 1, Fahim Barmak 1, Clive Veerapal 1, Naushaba Khan 1, Kirsten Cherian 1, Emily Felber 1, Randi Brown 1, Elizabeth Choi 1, Sinead King 1, Heather Pankow 1, James H Bishop 1, Azeezat Azeez 1, John Coetzee 1, Rachel Rapier 1, Nicole Odenwald 1, David Carreon 1, Jessica Hawkins 1, Maureen Chang 1, Jennifer Keller 1, Kristin Raj 1, Charles DeBattista 1, Booil Jo 1, Flint M Espil 1, Alan F Schatzberg 1, Keith D Sudheimer 1, Nolan R Williams 1
Affiliations expand
- PMID: 34711062
- DOI: 10.1176/appi.ajp.2021.20101429
Abstract
Objective: Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is approved by the U.S. Food and Drug Administration for the treatment of treatment-resistant depression but is limited by suboptimal efficacy and a 6-week duration. The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT). This protocol was associated with a remission rate of ∼90% after 5 days of open-label treatment. Here, the authors report the results of a sham-controlled double-blind trial of SNT for treatment-resistant depression.